192 related articles for article (PubMed ID: 35344842)
1. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
Park JH; Park I; Kim IH; Hur JY; Hwang I; Kim C; Kim HJ; Maeng CH; Park K; Lee MY; Lee HJ; Jung JY; Keam B; Park SH; Lee JL
Curr Probl Cancer; 2022 Jun; 46(3):100848. PubMed ID: 35344842
[TBL] [Abstract][Full Text] [Related]
2. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
3. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
[TBL] [Abstract][Full Text] [Related]
4. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
5. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
[TBL] [Abstract][Full Text] [Related]
6. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Wright JL; Yu EY; Montgomery RB; Hsieh AC; Grivas P; Khaki AR
Clin Genitourin Cancer; 2022 Dec; 20(6):558-567. PubMed ID: 36155169
[TBL] [Abstract][Full Text] [Related]
7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
8. Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
Labidi S; Meti N; Barua R; Li M; Riromar J; Jiang DM; Fallah-Rad N; Sridhar SS; Del Rincon SV; Pezo RC; Ferrario C; Cheng S; Sacher AG; Rose AAN
BMJ Open; 2024 Mar; 14(3):e081480. PubMed ID: 38553056
[TBL] [Abstract][Full Text] [Related]
9. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
10. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
[TBL] [Abstract][Full Text] [Related]
11. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
12. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
Bellmunt J; Choueiri TK; Fougeray R; Schutz FA; Salhi Y; Winquist E; Culine S; von der Maase H; Vaughn DJ; Rosenberg JE
J Clin Oncol; 2010 Apr; 28(11):1850-5. PubMed ID: 20231682
[TBL] [Abstract][Full Text] [Related]
14. First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis.
Lin CT; Su PJ; Huang SY; Wu CC; Wang HJ; Cheng YT; Luo HL; Chen CH; Liu TT; Huang CC; Su YL
J Immunother; 2022 Nov-Dec 01; 45(9):407-414. PubMed ID: 36121316
[TBL] [Abstract][Full Text] [Related]
15. Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice.
Mencinger M; Mangaroski D; Bokal U
Radiol Oncol; 2021 May; 55(4):491-498. PubMed ID: 33939898
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
Wong RL; Ferris LA; Do OA; Holt SK; Ramos JD; Crabb SJ; Sternberg CN; Bellmunt J; Ladoire S; De Giorgi U; Harshman LC; Vaishampayan UN; Necchi A; Srinivas S; Pal SK; Niegisch G; Dorff TB; Galsky MD; Yu EY
Oncologist; 2021 Dec; 26(12):1026-1034. PubMed ID: 34355457
[TBL] [Abstract][Full Text] [Related]
17. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
Bamias A; Merseburger A; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627145
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
19. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
20. Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy.
Elumalai T; Croxford W; Buijtenhuijs B; Conroy R; Sanderson B; Enting D; Aversa C; Doss G; Das A; Vasudev NS; Kitetere E; Tolan S; Law A; Hoskin P; Mistry H; Choudhury A
Clin Oncol (R Coll Radiol); 2022 Oct; 34(10):642-652. PubMed ID: 35282933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
